Physician profile
Jessica J Slaba
NPI 1770190993
$40,944.73
in general payments reported to CMS, 2019-2025
22 companies · $37K in 2025
The $37K reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $16.05 · 2023: $85.93 · 2024: $4,032 · 2025: $37K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $31K · Travel and Lodging: $5,887 · Food and Beverage: $2,424 · Consulting Fee: $1,635.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $30,982.00 |
| Travel and Lodging | $5,887.23 |
| Food and Beverage | $2,424.45 |
| Consulting Fee | $1,635.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Geron Corporation | $30,716.27 | 2025 | Rytelo |
| E.R. Squibb & Sons, L.L.C. | $9,004.11 | 2024-2025 | Reblozyl |
| Celgene Corporation | $390.74 | 2023-2024 | Reblozyl |
| Legend Biotech USA INC. | $107.95 | 2024-2025 | Carvykti |
| Abbvie INC. | $83.61 | 2024 | |
| Novartis Pharmaceuticals Corporation | $79.29 | 2024 | |
| Astrazeneca Pharmaceuticals Lp | $76.71 | 2023-2025 | Calquence |
| Janssen Biotech, INC. | $70.89 | 2024-2025 | Tecvayli, Carvykti, Talvey |
| Beigene USA, INC. | $60.01 | 2023-2024 | Brukinsa |
| Rigel Pharmaceuticals, INC. | $39.47 | 2024 | Rezlidhia, Tavalisse |
| Genentech USA, INC. | $38.22 | 2023-2024 | Polivy, Columvi, Lunsumio |
| Regeneron Healthcare Solutions, INC. | $37.75 | 2025 | Lynozyfic |
| Genzyme Corporation | $37.72 | 2025 | |
| Adc Therapeutics America, INC. | $35.82 | 2024-2025 | |
| Daiichi Sankyo INC. | $35.02 | 2024 | Vanflyta, Enhertu |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genmab U.S., INC. | $26.20 | 2024 | Epkinly |
| Incyte Corporation | $24.39 | 2024 | Jakafi |
| Pharmaessentia USA Corporation | $19.04 | 2024 | Besremi |
| Astellas Pharma US INC | $17.06 | 2024 | Xospata |
| Adaptive Biotechnologies Corporation | $16.05 | 2022 | |
| Teleflex LLC | $14.47 | 2025 | Arrow |
| Janssen Scientific Affairs, LLC | $13.94 | 2025 | Carvykti, Tecvayli, Talvey |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Slaba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.